EMBARQ CORPORATION

EQ

Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its third fiscal quarter ended September 30, 2025.

Equillium, Inc. ( EQ ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases November 5, 2025 12:00 PM EST Company Participants Bruce Steel - Co-Founder, CEO & Director Stephen Connelly - Chief Scientific Officer & President Francisco Quintana Brian Gordon Feagan Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Cha Cha Yang - Jefferies LLC, Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Brian Feagan Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Min Lee - Guggenheim Securities, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Equillium Bio Virtual KOL Event.

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Stifel Healthcare Conference Format: Company Presentation & 1x1 Meetings Date: Wednesday, November 12, 2025 Time: 3:20-3:50 PM EDT Jefferies Global Healthcare Conference in London Format: 1x1 Meetings Date: Tuesday, November 18 – Thursday, November 20, 2025 Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.

LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase a total of 7,200 shares of common stock to a new employee under Equillium's 2024 Inducement Plan.

Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates.

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

While last month ended up being a decent one for the Nasdaq Composite, it was downright fantastic for a handful of Nasdaq-listed names. Here's a rundown of the Nasdaq Composite's five-best performing stocks that blew the index's 1.6% August gain out of the water.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.